13589-08-7

Basic information

• Product Name: (S,S)-N,N'-bis(1-carboxy-2-phenylethyl)urea
• Synonyms: (S,S)-N,N'-bis(1-carboxy-2-phenylethyl)urea
• CAS NO: 13589-08-7
• Molecular Weight: 356.378
• Mol File: 13589-08-7.mol

Chemical Properties

• CAS DataBase Reference: (S,S)-N,N'-bis(1-carboxy-2-phenylethyl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: (S,S)-N,N'-bis(1-carboxy-2-phenylethyl)urea(13589-08-7)
• EPA Substance Registry System: (S,S)-N,N'-bis(1-carboxy-2-phenylethyl)urea(13589-08-7)

Safety Data

• Hazardous Substances Data: 13589-08-7(Hazardous Substances Data)

Upstream product

• 70779-93-0 N,N'-carbonyl-bis-phenylalanine diethyl ester 
• 75-44-5 phosgene 
• 1795-96-6 phenylalanine ethyl ester 
• 13464-19-2 phenyl chlorothioformate 
• 673-06-3 D-(R)-phenylalanine 
• 109-99-9 tetrahydrofuran 
• 150-30-1 Phenylalanine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 2462-32-0 L-phenylalanine benzyl ester hydrochloride 
• 7524-50-7 methyl (2S)-2-amino-3-phenylpropanoate hydrochloride 
• 26416-38-6 2-[3-(1-methoxycarbonyl-2-phenylethyl)ureido]-3-phenylpropionic acid methyl ester 
• 63-91-2 L-phenylalanine 
• 14825-82-2 L-phenylalanine-N-carboxyanhydride 

Downstream Products

• 70779-93-0 N,N'-carbonyl-bis-phenylalanine diethyl ester 
• 13589-09-8 5-benzyl-3-(1-carboxy-2-phenylethyl)hydantoin 
• 70779-93-0 (S,S)-N,N'-bis[1-(ethoxycarbonyl)-2-phenylethyl]urea 

Relevant articles and documents

Short self-assembling peptides with a urea bond: A new type of supramolecular peptide hydrogel materials

There is an increasing need to develop short self-assembling peptides (SAPs) that can form hydrogels for cell engineering and biomedical applications. In this study, we proposed new short self-assembling peptides with a symmetric structure via a urea bond

Biofunctional supramolecular hydrogels fabricated from a short self-assembling peptide modified with bioactive sequences for the 3D culture of breast cancer MCF-7 cells

Self-assembling peptides are a type of molecule with promise as scaffold materials for cancer cell engineering. We have reported a short self-assembling peptide, (FFiK)2, that had a symmetric structure connected via a urea bond. In this study, we functionalized (FFiK)2 by conjugation with various bioactive sequences for the 3D culture of cancer cells. Four sequences, RGDS and PHSRN derived from fibronectin and AG73 and C16 derived from laminin, were selected as bioactive sequences to promote cell adhesion, proliferation or migration. (FFiK)2, and its derivatives could co-assemble into supramolecular nanofibers displaying bioactive sequences and form hydrogels. MCF-7 cells were encapsulated in functionalized peptide hydrogels without significant cytotoxicity. Encapsulated MCF-7 cells proliferated under 3D culture conditions. MCF-7 cells proliferated with spheroid formation in hydrogels that displayed RGDS or PHSRN sequences, which will be able to be applied to drug screening targeting cancer stem cells. On the other hand, since MCF-7 cells migrated in a 3D hydrogel that displayed AG73, we could construct the metastatic model of breast cancer cells, which is helpful for the elucidation of breast cancer cells and drug screening against cancer cells under metastatic state. Therefore, functionalized (FFiK)2 hydrogels with various bioactive sequences can be used to regulate cancer cell function for tumor engineering and drug screening.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of Formulas I-VI, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth. Formula I is exemplified below: Formula (i)

LATENT INHIBITORS. PART 4. IRREVERSIBLE INHIBITION OF DIHYDRO-OROTATE DEHYDROGENASE BY HYDANTOINS DERIVED FROM AMINO ACIDS

Hydantoins and ureas derived from α-amino acids are shown to interact with dihydro-orotate dehydrogenase from Clostridium (Zymobacterium) oroticum, chiefly as weak competitive inhibitors but that the hydantoin derived from phenylalanine, 5-benzyl-3-(1-car